News Center

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 8, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 27 th Annual Credit Suisse Healthcare Conference on Wednesday, November 14 th , 2018 at 2:15 p.m. Mountain Time ( 4:15 p.m.

– LINZESS ® (linaclotide) U.S. net sales increased 7% to $205 million in 3Q 2018 vs 3Q 2017 – – Ironwood revenue of $66 million in 3Q 2018, which includes a $30 million reduction due to LINZESS change in estimate as reported to Ironwood by Allergan – – Received Fast Track Designation for

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 25, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its third quarter 2018 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, November 6, 2018 . Individuals interested in participating in the

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 8, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotechnology company, today announced the presentation of clinical data for IW-3718 and linaclotide from the company and its collaborators during the American College of Gastroenterology